BriaCell Therapeutics Corp.
BCTXHealthcare|Biotechnology|CA
$3.95
+0.68 (+20.80%)
DCF Value
$0.59
Tangible Book / Share
$1.77
Cash / Share
$2.36
Clinical Trials (4)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06072612 Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. | Breast Cancer, Metastatic Breast Cancer | P3 | Recruiting | 404 | RCT, Open-label | SV-BR-1-GM, Cyclophosphamide, Interferon infiltration of the inoculation site, Retifanlimab, Treatment of Physician's Choice |
| NCT03066947 SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer | Breastcancer, Breast Neoplasm | P1P2 | Completed | 24 | Open-label | SV-BR-1-GM, Cyclophosphamide, Interferon-alpha-2b |
| NCT06471673 A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer | Breast Cancer, Breast Tumor | P1P2 | Unknown | 18 | Open-label | BC1 cell line, Bria-OTS regimen and CPI (tislelizumab), Bria-OTS regimen and CPI (tislelizumab) expansion cohort |
| NCT03328026 Combination Study of SV-BR-1-GM With Retifanlimab | Breast Cancer, Breast Neoplasm | P1P2 | Completed | 36 | RCT, Open-label | SV-BR-1-GM, Low dose cyclophosphamide, Interferon Inoculation, retifanlimab |